FDA Discounts Advisory Panel’s Advice, Says Lilly’s Depot Zyprexa “Not Approvable”
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency seeks more information on olanzapine depot's sedation effect.
You may also be interested in...
Long-Acting Atypical Antipsychotic Market Snapshot: A One-Company Market Begins To Diversify
Otsuka and Lundbeck’s newly approved long-acting antipsychotic Abilify Maintena enters a sub-sector of the anti-psychotic market dominated by Johnson & Johnson for the last decade, but the new competitor may be able to gain ground by helping to grow the patient population.
Alkermes Unveils Bydureon Royalties And Its Own Long-acting Form Of Lilly's Zyprexa
Risperdal Consta will be cash cow for years to come, but other drugs in pipeline will fill out revenue stream.
Alkermes Unveils Bydureon Royalties And Its Own Long-acting Form Of Lilly's Zyprexa
Risperdal Consta will be cash cow for years to come, but other drugs in pipeline will fill out revenue stream.